

# Stakeholder Voices – Perspectives of Clinicians & Health Systems

NIDA CTN ED Research Meeting: Advancing ED-initiated Buprenorphine

*Arjun Venkatesh MD, MBA, MHS*  
*Department of Emergency Medicine*  
*@arjunvenkatesh*

Yale SCHOOL OF MEDICINE



# Today's Lineup



Tania D. Strout, PhD, RN, MS  
Director of Research, Associate Professor  
Department of Emergency Medicine, Maine Medical Center  
Tufts University School of Medicine




Adam L. Sharp, MD, MSc  
Emergency physician, Los Angeles Medical Center  
Research Scientist at Kaiser Permanente Southern California (KPSC)  
Director of Academic Affairs for KP Bernard J. Tyson School of Medicine



Jason Wilson, M.D., M.A., CPHQ, FACEP,  
Medical Director, Clinical Decision Unit, Tampa General Hospital;  
Associate Medical Director of Adult ED, TEAMHealth;  
Associate Professor, Department of Internal Medicine, Morsani  
College of Medicine, University of South Florida

# Does COVID change the role or capacity of the ED in treatment for OUD?

Figure 1. Count of Emergency Department (ED) Visits for All Drug and Opioid Overdoses (ODs), Intimate Partner Violence (IPV), Suicide Attempts (SAs), Mental Health Conditions (MHCs), and Suspected Child Abuse and Neglect (SCAN) in the US, December 30, 2018, to October 10, 2020



# What research do clinicians need at the bedside?

THE PRACTICE OF EMERGENCY MEDICINE/CONCEPTS


## Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department



Kathryn Hawk, MD, MHS\*; Jason Hoppe, DO; Eric Ketcham, MD; Alexis LaPietra, DO; Aimee Moulin, MD; Lewis Nelson, MD; Evan Schwarz, MD; Sam Shahid, MBBS, MPH; Donald Stader, MD; Michael P. Wilson, MD; Gail D'Onofrio, MD, MS


... yet we currently  
treat 40 / 100K  
ED visits

Figure. Trends in the Use of Buprenorphine in Emergency Departments (EDs) per 100 000 Visits in the United States, 2002-2017



Rhee, JAMA Open, 2020

# What research do providers need to change policy?



Buprenorphine Waiver Notification

System Use Notification

- You are accessing a U.S. Government information system, which includes (1) this computer, (2) this computer network, (3) all computers connected to this network, and (4) all devices and storage media attached to this network or to a computer on this network. This information system is provided for U.S. Government-authorized use only.
- Unauthorized or improper use of this system is prohibited and may result in disciplinary action, as well as civil and criminal penalties.
- Personal use of social media on this system may result in disciplinary action unless otherwise authorized.

By using this information system, you understand and consent to the following:

- You have no reasonable expectation of privacy regarding any communication or data transiting or stored on this information system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this information system.
- The government may record and audit your information system usage, including usage of personal email systems to conduct HHS business.
- Any communication or data transiting or stored on this information system may be disclosed or used for any lawful Government purpose.

To bridge educational gaps and build provider confidence in buprenorphine administration, **Get Waivered** presents the

## X-press X-waiver E-Course

Delivering clinical best practices from the traditional 8-hour virtual training in just **8 minutes**

Register for this free Zoom-based training at [getwaivered.com/remote](https://getwaivered.com/remote)

### COURSE AGENDA

- Notice of Intent (NOI) Submission
- 8-minute Core Content
- Expert Q&A Panel (optional)

Interested in expediting the process? Submit your NOI in < 15 clicks!

After gathering your NPI and DEA numbers, use the following roadmap to complete your NOI in 90 seconds:

# Open Discussion

Yale SCHOOL OF MEDICINE

